Fact CheckerSign in

NCT06576544Enrolling by invitation

Wearables to Define Postpartum Blood Pressure Trajectories and Facilitate Evidence-based Monitoring Guidelines

Evidence-Based Prediction and Prevention of Adverse Outcomes Caused by Postpartum Hypertension

Source: ClinicalTrials.gov · Last updated 4 Nov 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

To better understand postpartum blood pressure changes, the investigators are proposing a study to monitor blood pressure after delivery in 100 patients who the investigators expect to have normal blood pressure (i.e. low-risk group), 100 patients who the investigators expect to be at risk of new-onset high blood pressure postpartum (i.e. intermediate-risk group), and 100 patients who had high blood pressure prior to pregnancy (or very early, before 20 weeks in pregnancy) who the investigators know are at high risk of blood-pressure related complications postpartum (i.e. high-risk group). Patients will be given a non-invasive wearable device that monitors blood pressure continuously for 6 weeks postpartum. The investigators expect that the daily changes in blood pressure will be different between these groups, which may allow us to better predict who is at risk, how much monitoring is needed, and when to intervene before the blood pressure abnormalities cause complications. The blood pressure device that will be given to patients is the YHE® BP Doctor Med Blood Pressure Smartwatch. This is a highly-accurate medical grade device that has not received FDA clearance. As such, the device is not being used to make blood pressure management and treatment decisions, but rather to gather data on postpartum cardiovascular physiology. Safety stops are built into the protocol such that elevated readings detected by the watch will trigger clinical referrals and validation by standard blood pressure cuffs prior to determine need for treatment.

Status (registry)
Enrolling by invitation
Study type
Observational
Enrollment
300 (estimated)
First submitted
26 Aug 2024
Start date
Oct 2024
Primary completion date
Jun 2026
Lead sponsor
University of California, San Diego
NCT number
NCT06576544

What you commit to

  • Study type: Observational
  • Planned participants: 300
  • From Oct 2024 to the primary completion date, Jun 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Initiation of antihypertensive therapy prior to discharge from delivery hospitalization.

Other illness

  • Institutionalization for psychiatric disorder, mental deficiency or incarcerated

Other

  • Inability to give informed consent

Who the study is looking for

  • Postpartum birthing person 18 years of age or older
  • At least 20 weeks gestation at time of delivery
  • Meeting criteria for 1 of 3 risk categories for PP HTN and hypertensive morbidity
  • Planned postpartum care at UCSD

Age in the registry: 18 years to 50 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Jacobs Medical Center at UC San Diego Health
Coordinator of this site? Confirm its status
La JollaUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.